Minor ABO-Incompatible Bone Marrow Transplantation in β-Thalassemia Major

Al-Nuri, Rana Nidhamaldeen; Ipsevich, Francesco

doi:10.33899/iraqij.p.2026.168991.1184

	Minor ABO-Incompatible Bone Marrow Transplantation in β-Thalassemia Major
Iraqi Journal of Pharmacy
Article 5, Volume 23, Issue 1, March 2026, Pages 40-44 PDF (724.81 K)
Document Type: Case Report
DOI: 10.33899/iraqij.p.2026.168991.1184
Authors
Rana Nidhamaldeen Al-Nuri^* ¹; Francesco Ipsevich²
¹Al Had-baa Specialized Hospital for Hematology and Bone Marrow Transplantation, Mosul, Iraq
²Stem Cell Collection Unit, San Camillo-Forlanini Hospital, Rome, Italy
Abstract
Background: Allogeneic bone marrow transplantation (BMT) primarily requires human leukocyte antigen (HLA) compatibility, whereas ABO blood group compatibility is not mandatory. However, transplantation across major or minor ABO incompatibility may result in clinically significant complications, including hemolysis, delayed engraftment, and Passenger Lymphocyte Syndrome (PLS). Elevated anti-ABO antibody titers in either donor or recipient can compromise transplant outcomes. Careful pre-transplant immunohematological evaluation is therefore essential to minimize these risks. Aim: This study aimed to prevent hemolytic complications, optimize engraftment, and improve clinical outcomes in a case of major ABO-incompatible allogeneic BMT. Methods: A retrospective descriptive case study was conducted on a nine-year-old female patient diagnosed with major β-thalassemia, blood group B, scheduled for allogeneic BMT from her HLA-identical (100% match) brother with blood group O. Donor anti-ABO antibody titers were measured using the standard tube agglutination method with serial serum dilutions. Testing was performed using immediate spin (IS) and anti-human globulin (AHG) phases against B-group red blood cells. Based on antibody titration results, the harvested bone marrow graft underwent appropriate cell manipulation prior to infusion. Post-transplant monitoring included clinical assessment and laboratory evaluation for evidence of PLS and engraftment kinetics. Results: Donor anti-B antibody titers were 1:32 at the IS phase and 1:256 at the AHG phase, indicating significant IgG-mediated reactivity. Following graft manipulation, total nucleated cell recovery was 98.5%, while CD34⁺ stem cell recovery was 88.3%, remaining within an acceptable therapeutic range. The patient received the manipulated graft without acute hemolytic complications. Serial clinical and laboratory evaluations revealed no evidence of PLS. Successful hematopoietic engraftment was subsequently achieved. Conclusion: Pre-transplant quantification of anti-ABO antibodies and appropriate graft manipulation can effectively mitigate hemolytic risk in major ABO-incompatible BMT. This individualized approach supports safe engraftment and favorable clinical outcomes, emphasizing the importance of immunohematological assessment in ABO-mismatched transplantation settings.
Keywords
ABO incompatibility; Bone marrow transplantation; Engraftment; Graft; Manipulation; Passenger Lymphocyte Syndrome

References
Rožman P, Košir A, Bohinjec M. Is the ABO incompatibility a risk factor in bone marrow transplantation? Transplant immunology 2005;14(3-4):159-69. Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biology of Blood Marrow Transplant 2013;19(8):1152-8. Vaezi M, Dameshghi DO, Souri M, Setarehdan SA, Alimoghaddam K, Ghavamzadeh A. ABO incompatibility and hematopoietic stem cell transplantation outcomes. International Journal of Hematology-Oncology and Stem Cell Research 2017;11(2):139. Logan AC, Wang Z, Alimoghaddam K, Wong RM, Lai T, Negrin RS, et al. ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 2015;21(4):746-54. Buckner C, Clift R, Sanders J, Williams B, Gray M, Storb R, et al. ABO-Incompatible marrow transplant, Transplantation 1978;26(4):233-8. Tekgündüz SA, Özbek N. ABO blood group mismatched hematopoietic stem cell transplantation. Transfusion and Apheresis Science 2016;54(1):24-9. Gajewski JL, Johnson VV, Sandler SG, Sayegh A, Klumpp TR. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008;112(8):3036-47. Ghavamzadeh A, Iravani M, Ashouri A, Mousavi SA, Mahdavi N, Shamshiri A, et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biology of Blood and Marrow Transplantation 2008;14(3):301-8. Grube M, Wolff D, Ahrens N, Herzberg PY, Herr W, Holler E. ABO blood group antigen mismatch has an impact on outcome after allogeneic peripheral blood stem cell transplantation. Clinical Transplantation 2016;30(11):1457-65. Migdady Y, Pang Y, Kalsi SS, Childs R, Arai S. Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics. Blood Advances 2022;6(8):2707-21. Seebach JD, Stussi G, Passweg JR, Loberiza Jr FR, Gajewski JL, Keating A, et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biology of Blood and Marrow Transplantation 2005;11(12):1006-13. Ludajic K, Balavarca Y, Bickeböller H, Rosenmayr A, Fischer GF, Faé I,et al. Minor ABO-mismatches are risk factors for acute graft-versus-host disease in hematopoietic stem cell transplant patients. Biology of blood and marrow transplantation 2009;15(11):1400-6. Watz E, Remberger M, Ringden O, Lundahl J, Ljungman P, Mattsson J, et al. Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning. Biology of Blood and Marrow Transplantation 2014;20(2):264-71. Smith EP. Hematologic disorders after solid organ transplantation. American Society of Hematology. Education Program 2010;1:281-6. Haruka Teshigawara-Tanabe MH, Ayako Matsumura, Hiroyuki Takahashi, Yuki Nakajima, Takuya Miyazaki, Aki Kamijo, Etsuko Yamazaki, Katsumichi Fujimaki, Kenji Matsumoto, Hideaki Nakajima. Passenger lymphocyte syndrome after ABO-incompatible allogeneic hematopoietic stem cell transplantation; dynamics of ABO allo-antibody and blood type conversion. Hematology 2021;26(1):835-9. Pan Y, Zhao A, Jiang X, Zhou N, Wang J, Sun C, et al. Passenger lymphocyte syndrome—Epidemiology, pathogenesis, diagnosis, treatment and future directions: A review. Biomolecules and Biomedicine 2025;26(2):215. Petz LD, editor Immune hemolysis associated with transplantation. Seminars in hematology 2005; 42(3): 145-55. Nadarajah L, Ashman N, Thuraisingham R, Barber C, Allard S, Green L. Literature review of passenger lymphocyte syndrome following renal transplantation and two case reports. American journal of Transplantation 2013;13(6):1594-600. Bolan CD, Childs RW, Procter JL, Barrett AJ, Leitman SF. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. British journal of haematology 2001;112(3):787-95. Dubey AP, Hemchandra; Sonker, Atul; Chaudhary, Rajendra K. A case of passenger lymphocyte syndrome following minor ABO incompatible renal transplantation. Asian Journal of Transfusion Science 2014;8(1):56-8. Worel N. ABO-mismatched allogeneic hematopoietic stem cell transplantation. Transfusion Medicine and Hemotherapy 2016;43(1):3-12. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. The Lancet 2007;370(9585):415-26. Ma Y-R, Wang W-J, Cheng Y-F, Zhang Y-Y, Mo X-D, Han T-T, et al. Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplantation 2020;55(6):1068-75.
Statistics Article View: 204 PDF Download: 180